glycine has been researched along with Embolism, Pulmonary in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with a fixed dose of oral ximelagatran, used without routine coagulation monitoring, showed reproducible pharmacokinetics and pharmacodynamics with a rapid onset of action and promising clinical results in patients with pulmonary embolism." | 9.10 | Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. ( Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K, 2002) |
| "Treatment with a fixed dose of oral ximelagatran, used without routine coagulation monitoring, showed reproducible pharmacokinetics and pharmacodynamics with a rapid onset of action and promising clinical results in patients with pulmonary embolism." | 5.10 | Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. ( Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K, 2002) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| "The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations." | 2.70 | Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002) |
| "2." | 2.42 | [New anticoagulants in clinical practice]. ( Boda, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djordjevic, V | 1 |
| Mitic, G | 1 |
| Pruner, I | 1 |
| Kovac, M | 1 |
| Radojkovic, D | 1 |
| Lin, CC | 1 |
| Liu, PH | 1 |
| Kao, SJ | 1 |
| Chen, HI | 1 |
| Wåhlander, K | 2 |
| Lapidus, L | 1 |
| Olsson, CG | 1 |
| Thuresson, A | 1 |
| Eriksson, UG | 1 |
| Larson, G | 2 |
| Eriksson, H | 1 |
| Eriksson, BI | 2 |
| Agnelli, G | 1 |
| Cohen, AT | 1 |
| Dahl, OE | 1 |
| Mouret, P | 1 |
| Rosencher, N | 1 |
| Eskilson, C | 1 |
| Nylander, I | 1 |
| Frison, L | 2 |
| Ogren, M | 1 |
| Weltermann, A | 1 |
| Kyrle, PA | 1 |
| Eichinger, S | 1 |
| Boda, Z | 1 |
| Nielsen, JD | 1 |
| Reuner, KH | 1 |
| Ruf, A | 1 |
| Litfin, F | 1 |
| Patscheke, H | 1 |
| Lindahl, TL | 1 |
| Andersson, C | 1 |
| Gustafsson, D | 1 |
| Bylock, A | 1 |
3 reviews available for glycine and Embolism, Pulmonary
| Article | Year |
|---|---|
Novel anticoagulants for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondapa | 2003 |
[New anticoagulants in clinical practice].
Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C; | 2004 |
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzyla | 2005 |
3 trials available for glycine and Embolism, Pulmonary
3 other studies available for glycine and Embolism, Pulmonary
| Article | Year |
|---|---|
Are thrombophilia more multifactorial than we thought: report of mosaicism for FII G20210A and novel FII T20061C gene variants.
Topics: Alanine; Biomarkers; Cysteine; Female; Genotype; Glycine; Humans; Hypertension, Pulmonary; Middle Ag | 2012 |
Effects of phorbol myristate acetate and sivelestat on the lung injury caused by fat embolism in isolated lungs.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Embolism, Fat; Gly | 2012 |
The mutation G20210-->A in the prothrombin gene is a strong risk factor for pulmonary embolism.
Topics: Adolescent; Adult; Aged; Alanine; Female; Glycine; Humans; Male; Middle Aged; Mutation; Prothrombin; | 1998 |